Effects of added l-carnitine, acetyl-CoA and CoA on peroxisomal beta-oxidation of [U-14C]hexadecanoate by isolated peroxisomal fractions.
(1) During peroxisomal beta-oxidation of [U-14C]hexadecanoate, at concentrations higher than 100 microM, long-chain 3-oxoacyl-CoA-esters and 3-oxobutyryl-CoA accumulate. Only 3-oxobutyryl-CoA accumulates at a low concentration of [U-14C]hexadecanoate. Accumulation of long chain 3-oxoacyl-CoA esters is most extensive when the supply of CoA can be considered limiting for beta-oxidation. (2) Added acetyl-CoA was found to inhibit peroxisomal beta-oxidation. This inhibition was not significantly relieved by added L-carnitine and carnitine acetyltransferase (EC 2.3.17). (3) Added L-carnitine, at concentrations below 0.2 mM, was found to stimulate peroxisomal beta-oxidation of [U-14C]hexadecanoate by up to 20%, causing the conversion of acetyl-CoA into acetylcarnitine. Higher concentrations of L-carnitine were progressively inhibitory to beta-oxidation. This effect was specific for L-carnitine as both D-carnitine and aminocarnitine neither caused stimulation at low concentrations, nor inhibition at higher concentrations. Added L-carnitine caused accumulation of acylcarnitines of chain-lengths ranging from 4 to 16 carbon-atoms. The inhibition observed with higher concentrations of added L-carnitine is likely due to conversion of [U-14C]hexadecanoate into [U-14C]hexadecanoylcarnitine. (4) Low concentrations of added hexadecanoylcarnitine was shown to inhibit peroxisomal beta-oxidation by about 15%, while added acetylcarnitine did not inhibit at concentrations up to 100 microM. (5) These data are interpreted to indicate significant control being exerted on flux at the stage of thiolysis either directly by means of CoA availability, or indirectly by means of the rate of acetyl-CoA generation.
Sleboda
J
J
Department of Physiology and Biochemistry, University of Oslo, Norway.
Pourfarzam
M
M
Bartlett
K
K
Osmundsen
H
H
D000105:Acetyl Coenzyme A / Q000494:pharmacology*; D000214:Acyl Coenzyme A / Q000378:metabolism; D000818:Animals; D001622:Betaine / Q000031:analogs & derivatives / Q000494:pharmacology; D002331:Carnitine / Q000494:pharmacology*; D002333:Carnitine Acyltransferases / Q000037:antagonists & inhibitors; D002458:Cell Fractionation; D003065:Coenzyme A / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008099:Liver / Q000378:metabolism; D008297:Male; D008830:Microbodies / Q000378:metabolism*; D010084:Oxidation-Reduction; D019308:Palmitic Acid; D010169:Palmitic Acids / Q000378:metabolism* / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D000214:Acyl Coenzyme A; D004791:Enzyme Inhibitors; D010169:Palmitic Acids; D019308:Palmitic Acid; D001622:Betaine; D000105:Acetyl Coenzyme A; C045761:emeriamine; D002333:Carnitine Acyltransferases; D002331:Carnitine; D003065:Coenzyme A